Services-Computer Processing & Data PreparationSIC 7374
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Hinge Health, Inc. filings on SEC EDGAR ↗
Hinge Health, Inc. filed its Form 10-Q for the quarter ended September 30, 2026, reporting a dual-class common stock structure with 68,485,043 Class A and 12,786,259 Class B shares outstanding. The company highlights its expansion into Migraine and Gastrointestinal care programs and the acquisition of Cylinder Health, Inc., while cautioning that it has a history of net losses and may not achieve profitability.
Hinge Health reported record Q3 2026 results with revenue growing 52% year-over-year to $235 million and a significant increase in non-GAAP operating margin to 33%. The company raised its full-year 2026 revenue guidance to approximately $880 million and announced that President James Pursley will transition to a role on the Board of Directors in January 2027.
Term
Q3 2026
“Our strong performance continues to reflect our ability to deliver exceptional clinical outcomes, a better healthcare experience and lower client costs at scale. This focus on the triple aim, via a technology platform that scales and automates care delivery, is also resulting in a record sales season.”
Daniel Perez, Co-Founder and CEO
“We wouldn't be the company we are today if not for Jim. He's been instrumental in our scaling to over 3,200 clients. I'm grateful for all he's done and that he'll continue contributing to our success as a board member and advisor.”